The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...

Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial ...

Merck's KEYLYNK-001 trial showed Keytruda and Lynparza improved progression-free survival in BRCA non-mutated ovarian cancer patients. In the waveLINE-007 trial, zilovertamab vedotin with R-CHP ...

Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...

Merck (MRK) announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or ...

At the final analysis conducted by an independent Data Monitoring Committee, the KEYTRUDA plus LYNPARZA regimen demonstrated a statistically significant and clinically meaningful improvement in PFS ...